LLY—FDA approves new Cyramza indication—second-line CRC in conjunction with FOLFIRI: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm Cyramza is the “fully human Erbitux” LLY acquired in the 2008 buyout of ImClone.